










Cardo Medical, Inc.: Cardo Medical Announces Femur-First Versatility With Its Uni-Compartmental Knee System
Published in Business and Finance on Wednesday, February 18th 2009 at 4:33 GMT, Last Modified on 2009-02-18 04:34:29 by Market Wire

LOS ANGELES, CA--(Marketwire - February 18, 2009) - Cardo Medical (
Dr. Andrew Brooks, Chairman and Chief Executive Officer of Cardo Medical, stated, "The Cardo Medical Uni-Compartmental Knee system was our first commercially available arthroplasty system, and also set the standards of simplicity, versatility and reproducibility we design into all our system offerings. The Align 360 Uni-Compartmental Knee system enables surgeons the flexibility to choose between both a tibial-first or femoral-first referencing and resection surgical technique and approach. With its innovative alignment and conservative resection instrumentation, the system easily adapts to any surgeons' training and methodology, including use with mechanical or computer assisted surgical navigation. We are pleased to offer intra-operative versatility within all of our systems and continue to offer modularity and interchangeability, especially within our Align 360 knee platform. Our innovations especially with regards to instrumentation, surgical approaches and techniques enable surgeons to achieve excellent surgical outcomes."
About Cardo Medical, Inc.
Cardo Medical (
Cardo Medical works in small, focused development teams in concert with physicians to rapidly develop products from concept to launch. We are committed to exceeding the standards by which any device company is judged. Please visit our website at [ www.cardomedical.com ] for more information on the Align 360 Uni-Compartmental Knee System in addition to our portfolio of other Reconstructive and Spinal Implant systems.
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), regarding product development efforts and other non-historical facts about expectations, beliefs or intentions regarding the business, technologies and products, financial condition, strategies or prospects. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that any products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the ailments being studied or for other ailments. In addition, forward-looking statements also may be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. We do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.